OPHLY:OTCMKTS
小野藥品工業
US$4.98
arrow_upward
+1.12%(+0.055) 1 天
10月16日, GMT-4 16:00:00 · USD
search
所有股票代码
| 股票代码 | 价格 | 涨跌额 | 涨跌幅 |
|---|
insights_auto正在为 OPHLY 生成关键数据洞见…
开盘价
US$5.05
最高价
US$5.07
最低价
US$4.98
市值
1.20万亿
平均成交量
6.28万
成交量
2.09万
52 周最高价
US$5.75
52 周最低价
US$3.82
Beta 版
0.21
流通股数
14.96亿
员工人数
4206
开盘价
US$5.05
最高价
US$5.07
最低价
US$4.98
市值
1.20万亿
平均成交量
6.28万
成交量
2.09万
52 周最高价
US$5.75
52 周最低价
US$3.82
Beta 版
0.21
流通股数
14.96亿
员工人数
4206
新闻报道
来自网络来源和新闻合作伙伴
Traders Union
·
16小时前
投资者撤离科技股，标普500指数期货上涨
资料
Ono Pharmaceutical Co., Ltd. is one of the largest pharmaceutical companies in Japan. It is headquartered in Chuo-ku, Osaka, Japan, with its major plants in Higashinari-ku, Osaka, and Fujinomiya, Shizuoka., and its central research institute at Minase, Shimamoto-cho, Mishima District, Osaka.
Ono Pharmaceutical's roots go back to 1717 when Ichibei Ono started his dealer business of pharmaceuticals in Osaka. His business expanded and changed its name a few times, and became Ono Pharmaceutical Industrial Co., Ltd. in 1948.
Ono has been listed in Tokyo Stock Exchange since 1963. Its consolidated earnings in the half year ending in March 2018 were 16 billion Japanese yen.
Nivolumab, the cancer drug based on the research of Prof. Dr. Tasuku Honjo of Kyoto University, who received the Nobel Prize later in 2018, is marketed by both Ono Pharmaceutical and Bristol-Myers Squibb.
In 2024, Harvard University and Ono Pharmaceutical entered into a joint research and drug development agreement. Under it, promising projects to test therapeutic targets will be selected over 5 years under the guidance of Harvard's Office of Technology Development, and ONO will fund the work. Wikipedia
小野藥品工業简介